Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)

Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising que... Author: BeaconMedIC Added: 07/31/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts